rAAV Gene Therapy Pretreatment With CD19 Inhibition for Redosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The induction of innate and adaptive immune responses to adeno-associated virus (AAV) capsid, vector DNA, and transgene product hinders successful gene therapy by eliminating the product and transfected cells, leading to decreased transgene expression and pre-existing neutralizing antibodies (NAbs) that prohibit repeated dosing.
Innovation Solution
Administering a CD19 inhibitor, such as an anti-CD19 antibody, prior to AAV gene therapy to manage host immune responses and suppress long-lasting humoral immunity, allowing for improved transgene expression and redosing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If AAV gene therapy is administered, then transgene expression is achieved, but host immune responses are induced that eliminate the product and transfected cells
Solution Approach 1:
The patent applies preliminary action by administering a CD19 inhibitor before AAV gene therapy to preemptively suppress the host immune response. This prevents the immune system from eliminating the AAV product and transfected cells, thereby maintaining transgene expression without requiring post-therapy immune intervention.
2Productivity
If AAV gene therapy is administered, then transgene expression is achieved, but pre-existing neutralizing antibodies prohibit repeated dosing
Solution Approach 1:
The CD19 inhibitor is administered in advance to suppress the adaptive immune response and prevent the formation of neutralizing antibodies. This preliminary suppression enables repeated dosing of AAV gene therapy without the blocking effect of pre-existing NAbs, achieving both sustained transgene expression and redosing capability.
3Object-generated harmful factors
If anti-CD20 antibody is used to manage immune response, then B cell depletion is achieved, but long-lasting humoral immunity persists
Solution Approach 1:
The patent changes the target parameter from CD20 to CD19, which is expressed on B cells at all developmental stages including plasma cells. This parameter change enables depletion of both B cells and long-lived plasma cells, eliminating humoral immunity completely rather than leaving persistent long-lasting immunity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances transgene expression and permits redosing by reducing immune responses against AAV and transgene products, overcoming the limitations of existing anti-CD20 antibody strategies.
Implementation Method 1
The innate immune response to a gene therapy product (e.g., a recombinant AAV, i.e., rAAV) may eliminate the product and transfected cells... The adaptive immune response develops later, and plays a crucial role—it includes a humoral response characterized by the production of neutralizing antibodies (NAbs) specific to the capsid or an expressed transgene
Data Source
AI summary
Provided herein are methods for managing host immune responses to improve therapeutic outcomes in adeno-associated virus (AAV)-mediated gene therapy. Such methods may include administering a recombinant adeno-associated vims (rAAV) to a subject following administration of a CD 19 inhibitor, e.g., an anti-CD 19 antibody. The methods described herein can facilitate improved transgene expression, help overcome pre-existing NAbs, and/or permit redosing with the same or substantially similar rAAV or transgene.